Human HER2 Protein (C-His-Avi)

Cat # Size Price Quantity
80410125 ug$145
804102100 ug$295

Product Details


ApplicationELISA, BLI
FormatLiquid, Purified
Expression HostCHO
Target NameHER2, HER-2, ERBB2, CD340, neu, MLN19, NEU, NGL, TKR1
SpeciesHuman
SourcesRecombinant Human Her2 protein (Thr23-Thr652) with C-terminus His-Avi tag is expressed in CHO cells.
accession numberP04626
Molecular WeightThe protein has a predicted molecular weight of 73 kDa. Under DTT-reducing conditions, it migrates at approximately 85 kDa on SDS-PAGE.
Affinity TagC-His-Avi
Purity>95% based on SDS-PAGE under reducing condition
Formulation1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin levelNot tested
Protein Concentration25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and HandlingBriefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information


ErbB2, also known as HER2, is a receptor tyrosine kinase that belongs to the ErbB family, which includes EGFR, ErbB2, ErbB3, and ErbB4. It plays a critical role in regulating cell growth, differentiation, and survival. Unlike other members of the ErbB family, ErbB2 does not have a ligand-binding domain. However, it can form homodimers or heterodimers with other ErbB receptors after they bind their respective ligands, leading to activation of downstream signaling pathways. ErbB2 gene amplification and protein overexpression are observed in approximately 20% of invasive breast cancers, contributing to increased aggressiveness and poor prognosis. ErbB2 is also overexpressed in other cancers, including gastric, salivary, and colorectal cancers. Trastuzumab (Herceptin), a humanized monoclonal antibody targeting ErbB2, is used in the treatment of HER2-positive breast and gastric cancers.